Results 101 to 110 of about 28,302 (250)

Information Design for Early‐Stage Dose‐Finding Trials

Naval Research Logistics (NRL), EarlyView.
ABSTRACT To enhance enrollment rates in early‐stage dose‐finding clinical trials, we propose an information design approach, where the clinical investigator (CI) commits to an information releasing mechanism (IRM) based on the treatment's uncertain efficacy and toxicity to encourage patients to participate in the trial.
Amin Khademi, Ningyuan Chen
wiley   +1 more source

Motivations for Prescription Drug Misuse Related to Mental Health Problems in Adults. [PDF]

Subst Use Misuse, 2022
Drazdowski TK, Schulte M, Wolitzky-Taylor KB, Schaper H, Chapman JE.   +4 more
europepmc   +1 more source

The Uncharted Territory of the New Obesity Drugs in Users Without Obesity: A Sociomedical Perspective

Obesity, EarlyView.
ABSTRACT The off‐label use of glucagon‐like peptide‐1 receptor agonists (GLP‐1ra) among people without obesity and/or diabetes is rapidly expanding, despite a lack of clinical justification or safety data in this population. This Perspective explores the sociomedical dimensions of this trend, highlighting key research gaps and emerging hypotheses ...
Fernanda Baeza Scagliusi, Bruno Gualano, Pernille Andreassen, Cindi SturtzSreetharan, Sissel Due Jensen, Alexandra Brewis   +5 more
wiley   +1 more source

Prescription Drug Misuse with Alcohol Coingestion among US Adolescents: Youth Experiences, Health-related Factors, and Other Substance Use Behaviors. [PDF]

J Addict Med, 2023
Ford JA, McCabe SE, Schepis TS.
europepmc   +1 more source

Wernicke's Encephalopathy Following Semaglutide Treatment for Obesity: A Systematic PRISMA Review of Case‐Based Evidence

Obesity, EarlyView.
ABSTRACT Objective Glucagon‐like peptide‐1 receptor agonists are increasingly prescribed for obesity. Although generally considered safe, marked appetite suppression and persistent gastrointestinal adverse effects may increase the risk of nutritional deficiencies.
Janice Bidesie, Erik Oudman
wiley   +1 more source

Healthcare Resource Use and Cost: The Impact of Adopting an Abuse-Deterrent Formulation of Extended Release Morphine

ClinicoEconomics and Outcomes Research, 2020
Louis F Rossiter, 1 Winghan Jacqueline Kwong, 2 Elizabeth Marrett 2 1The College of William and Mary, Williamsburg, VA 23187, USA; 2US Medical Affairs, Daiichi Sankyo, Inc., Basking Ridge, NJ 07920, USACorrespondence: Elizabeth MarrettUS Medical ...
Rossiter LF, Kwong WJ, Marrett E
doaj  

Prevalence and Correlates of Prescription Drug Misuse in a Nationwide Population Survey in Taiwan. [PDF]

Int J Environ Res Public Health, 2021
Liu SW, Wu CY, Lee MB, Huang MC, Chan CT, Chen CY.   +5 more
europepmc   +1 more source

Physical activity and exercise participation—Impact on motor and non‐motor outcomes in early‐stage Parkinson disease: A cross‐sectional study

PM&R, EarlyView.
Abstract Background Aerobic exercise is beneficial in managing Parkinson disease (PD), yet its potential remains less clear in early stages. This study investigates the impact of long‐term aerobic exercise habits in individuals with early‐stage PD compared with healthy controls. Design Cross‐sectional study.
Cecilie Thrue, Frederik Bonde‐Jensen, Lars G. Hvid, Ulrik Dalgas, Martin Langeskov‐Christensen   +4 more
wiley   +1 more source

Intranasal diamorphine population pharmacokinetics modeling and simulation in pediatric breakthrough pain

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 435-447, March 2025.
Abstract Intranasal diamorphine (IND), approved for managing breakthrough pain in the UK, has been identified as an acceptable alternative offering effective, expedient, and less traumatic analgesia for children. However, the current dose regimen in pediatric populations relies on clinical expertise while the pharmacokinetics properties are poorly ...
Lianjin Cai, Jingchen Zhai, Beihong Ji, Fengyang Han, Taoyu Niu, Luxuan Wang, Junmei Wang   +6 more
wiley   +1 more source

Editorial: Prescribing psychotropics: Misuse, abuse, dependence, withdrawal and addiction, Volume II

Frontiers in Psychiatry, 2022
Stefania Chiappini, Stefania Chiappini, Fabrizio Schifano, Giovanni Martinotti, Giovanni Martinotti   +4 more
doaj   +1 more source